AbbVie, Galapagos Announces Joint Presentation
Product News Jun 16, 2015
Galapagos NV has announced a joint presentation with AbbVie at the 38th annual European Cystic Fibrosis Society conference in Brussels, Belgium.
"Development of Trafficking Assays to Evaluate Novel Corrector-Potentiator Combinations," presented by Dr Corina Balut of AbbVie, disclosed for the first time new assays developed by Galapagos and AbbVie to evaluate the impact of corrector molecules on the rescue of CFTR-F508del and to gain insight into the influence of each component in combination cocktails.
Among these was the combination of AVI-tagged CFTR with an MSD discovery platform to provide a more specific and sensitive approach in studying the endocytosis and degradation rate of plasma membrane CFTR. This particular new assay also characterizes the effect of various correctors on channel stability at the cell surface and its endocytosis/recycling, allowing for a better understanding of the mechanism of action of compounds.
The presentation is available for download on the Galapagos website.
Galapagos and AbbVie are working together to develop a triple combination therapy for cystic fibrosis patients with the Class II (F508del) mutation. Novel potentiator GLPG1837 is currently in Phase 1 and is expected to enter a Phase 2 study in class III mutation patients before end 2015.
Novel corrector GLPG2222 is expected to enter Phase 1 before end 2015. Galapagos and AbbVie expect to nominate a second novel corrector by Q3 2015 and thereby complete the triple combination therapy discovery phase. This second novel corrector is expected to enter Phase 1 in Q2 2016.